Kestra Medical beats Q3 revenue estimates; raises FY guidance

Kestra Medical Technologies

17/03/2026 20:21

Overview

US wearable medical device maker's fiscal Q3 revenue rose 63%, beating analyst expectations

Adjusted EBITDA loss for fiscal Q3 widened and missed analyst estimates

Company raised FY26 revenue guidance to $93 mln

Outlook

Kestra raises FY26 revenue guidance to $93 mln from $91 mln

Result Drivers

MARKET SHARE AND WCD MARKET EXPANSION - Revenue growth was driven by higher market share and expansion of the wearable cardioverter defibrillator market

IN-NETWORK PATIENTS AND REVENUE CYCLE - Revenue also benefited from a higher mix of in-network patients and improvements in revenue cycle management

GROSS MARGIN IMPROVEMENT - Gross margin expansion was driven by volume leverage, a higher mix of in-network patients and cost improvement programs

Company press release: ID:nGNX4S9wn

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$24.6 mln
$22.86 mln (7 Analysts)
Q3 EPS
-$0.61
Q3 Adjusted EBITDA
Miss
-$21.2 mln
-$20.74 mln (6 Analysts)
Q3 Gross Profit
$12.9 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Kestra Medical Technologies Ltd is $30.00, about 55.8% above its March 16 closing price of $19.26

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)